发明授权
- 专利标题: Anticoagulant fusion protein anchored to cell membrane
- 专利标题(中): 抗凝血融合蛋白锚定于细胞膜
-
申请号: US09402515申请日: 2000-02-02
-
公开(公告)号: US06423316B1公开(公告)日: 2002-07-23
- 发明人: Kristian Riesbeck , Anthony Dorling , Andrew John Timothy George , Robert Ian Lechler
- 申请人: Kristian Riesbeck , Anthony Dorling , Andrew John Timothy George , Robert Ian Lechler
- 优先权: GB9706327 19970326; GB9720248 19970923
- 主分类号: A61K3900
- IPC分类号: A61K3900
摘要:
The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).